Biogen upgraded to Outperform from Peer Perform at Wolfe Research
bullish
Public signal · 1-minute delayed
Source-backed market context you can read and share without an account.
bullish
What happened, with direct paths to the underlying reporting
Wolfe Research upgrades BIIB to Outperform; target $300; current price $208.87.
Target: $300
Posted price: $208.87
Analyst firm: Wolfe Research
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.